Maxim Group set a $6.00 target price on TrovaGene (NASDAQ:TROV) in a research report released on Wednesday, July 31st, TipRanks reports. The brokerage currently has a buy rating on the medical research company’s stock.
A number of other equities research analysts have also recently commented on TROV. ValuEngine upgraded shares of TrovaGene from a hold rating to a buy rating in a report on Tuesday, July 2nd. Zacks Investment Research downgraded shares of TrovaGene from a buy rating to a hold rating in a research report on Thursday, May 9th. Finally, Noble Financial set a $23.00 price objective on shares of TrovaGene and gave the company a buy rating in a research report on Friday, May 24th.
TROV stock traded down $0.30 during trading on Wednesday, reaching $1.94. The company had a trading volume of 995,200 shares, compared to its average volume of 578,692. The company has a market cap of $12.90 million, a P/E ratio of -0.23 and a beta of 0.74. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.20 and a quick ratio of 3.20. TrovaGene has a 52 week low of $1.30 and a 52 week high of $9.65. The business has a 50 day moving average of $2.01 and a 200 day moving average of $2.77.TrovaGene (NASDAQ:TROV) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.27). TrovaGene had a negative return on equity of 149.88% and a negative net margin of 3,424.46%. The business had revenue of $0.14 million during the quarter. Research analysts expect that TrovaGene will post -4.02 earnings per share for the current year.
Several large investors have recently modified their holdings of the business. Morgan Stanley grew its position in TrovaGene by 26,190.3% in the second quarter. Morgan Stanley now owns 27,079 shares of the medical research company’s stock worth $68,000 after acquiring an additional 26,976 shares in the last quarter. Vanguard Group Inc. boosted its position in TrovaGene by 320.8% during the second quarter. Vanguard Group Inc. now owns 285,150 shares of the medical research company’s stock valued at $713,000 after buying an additional 217,386 shares during the period. Renaissance Technologies LLC boosted its position in TrovaGene by 55.5% during the second quarter. Renaissance Technologies LLC now owns 249,121 shares of the medical research company’s stock valued at $623,000 after buying an additional 88,900 shares during the period. Finally, Wedbush Securities Inc. bought a new position in shares of TrovaGene during the second quarter valued at about $25,000. 7.24% of the stock is owned by institutional investors and hedge funds.
TrovaGene Company Profile
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Featured Article: What economic reports are most valuable to investors?
Receive News & Ratings for TrovaGene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TrovaGene and related companies with MarketBeat.com’s FREE daily email newsletter.